AOTI (AOTI) investor relations material

Executive summary

• Achieved 21% year-on-year revenue growth in H1 2025 to $31.8m, led by Medicaid and VA segments, despite significant U.S. market headwinds and regulatory disruptions.

• Maintained market leadership in topical oxygen therapy for chronic wounds, with strong clinical validation and international endorsements.

• Operational adjustments and cost containment measures implemented to address U.S. efficiency initiatives and the "Big Beautiful Bill" Act, particularly affecting Q2.

• Secured key validation milestones: California Medicaid Provider ID, Germany G-BA recommendation, and UK NICE guideline inclusion for TWO2Ⓡ therapy.

• Strategic focus on value-based care and durable wound healing, targeting high-cost areas like diabetic foot ulcers.

Financial highlights

• Revenues increased by 20.9% to $31.8m in H1 2025, with Q1 growth at 26% and Q2 slowing to 16% due to U.S. efficiency measures.

• Adjusted EBITDA declined 9.5% to $3.1m (margin 9.6%), reflecting higher operating expenses and investments for growth.

• Net profit of $0.2m in H1 2025, a turnaround from a $3.9m loss in H1 2024.

• Gross margin improved to 87.7% (up from 87.3%).

• Operating cash outflow was negative $4.7m, mainly due to delayed payments from Arizona Medicaid.

Outlook and guidance

• On track to deliver revised FY 2025 guidance: revenue growth in the mid-teens and low double-digit adjusted EBITDA margin.

• Trading in July and August consistent with guidance; growth trajectory expected to improve as headwinds subside.

• Expecting gradual revenue contributions from California, Germany, and the U.K. as new approvals and frameworks take effect.